"Same-Day" administration of pegfilgrastim following myelosuppressive chemotherapy: clinical practice and provider rationale.

about

Travel burden associated with granulocyte colony-stimulating factor administration in a Medicare aged population: a geospatial analysis.Administration options for pegfilgrastim prophylaxis: patient and physician preferences from a cross-sectional survey.

P2860

Q38672480-7095DE78-18ED-4715-85BD-FFED7E609F71 Q53121494-649FF0A5-04E3-4ABD-80B6-3C9F4A96FC16

P2860

"Same-Day" administration of pegfilgrastim following myelosuppressive chemotherapy: clinical practice and provider rationale.

Item

http://www.wikidata.org/entity/Q53161630

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh-hant

name

"Same-Day" administration of p ...... actice and provider rationale.

@en

"Same-Day" administration of p ...... actice and provider rationale.

@nl

type

Item

label

"Same-Day" administration of p ...... actice and provider rationale.

@en

"Same-Day" administration of p ...... actice and provider rationale.

@nl

prefLabel

"Same-Day" administration of p ...... actice and provider rationale.

@en

"Same-Day" administration of p ...... actice and provider rationale.

@nl

P1476

"Same-Day" administration of p ...... actice and provider rationale.

@en

P2093

Bintu Sherif

http://www.w3.org/2001/XMLSchema#string

Christina Darden

http://www.w3.org/2001/XMLSchema#string

David Chandler

http://www.w3.org/2001/XMLSchema#string

Jacob Garcia

http://www.w3.org/2001/XMLSchema#string

James A Kaye

http://www.w3.org/2001/XMLSchema#string

Mark A Price

http://www.w3.org/2001/XMLSchema#string

Sarah Marion

http://www.w3.org/2001/XMLSchema#string

Spiros Tzivelekis

http://www.w3.org/2001/XMLSchema#string

P2860

Pegfilgrastim on the Same Day Versus Next Day of Chemotherapy in Patients With Breast Cancer, Non-Small-Cell Lung Cancer, Ovarian Cancer, and Non-Hodgkin's Lymphoma: Results of Four Multicenter, Double-Blind, Randomized Phase II Studies.

Management of febrile neutropenia: ESMO Clinical Practice Guidelines.

Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel/cyclophosphamide chemotherapy.

Patterns of chemotherapy-associated toxicity and supportive care in US oncology practice: a nationwide prospective cohort study.

Evaluation of the Hematologic Safety of Same Day Versus Standard Administration (24- to 72-Hour Delay) of Pegfilgrastim in Gynecology Oncology Patients Undergoing Cytotoxic Chemotherapy.

Pegfilgrastim administered on the same day with dose-dense adjuvant chemotherapy for breast cancer is associated with a higher incidence of febrile neutropenia as compared to conventional growth factor support: matched case-control study of the Hell

Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice.

The safety and efficacy of day 1 versus day 2 administration of pegfilgrastim in patients receiving myelosuppressive chemotherapy for gynecologic malignancies.

Evaluating the total costs of chemotherapy-induced febrile neutropenia: results from a pilot study with community oncology cancer patients.

P2888

s00520-016-3193-3

P304

3889-3896

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00520-016-3193-3

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-04-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27108262

http://www.w3.org/2001/XMLSchema#string

"Same-Day" administration of pegfilgrastim following myelosuppressive chemotherapy: clinical practice and provider rationale.

about

P2860

P2860

"Same-Day" administration of pegfilgrastim following myelosuppressive chemotherapy: clinical practice and provider rationale.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698